Boston Scientific Corp. v. Stryker Corporation, No. 26-1171 (Fed. Cir. June 17, 2026)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Boston Scientific Corp. and Relievant Medsystems, Inc. (together, “Boston Scientific”) appeal a decision of the United States District Court for the District of New Jersey denying Boston Scientific’s request for a preliminary in- junction. The requested injunction would restrain Stryker Corporation (“Stryker”) from launching its OptaBlate BVN product on grounds that its sale would induce infringement of claims 16 and 21 of U.S. Patent No. 12,303,166 (the “’166 patent”).